Clinical Trial Update: Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

View source ↗

Summary

Real-world evidence study assessing the effectiveness of paritaprevir/ritonavir-ombitasvir + dasabuvir without ribavirin in chronic hepatitis C patients with co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Paritaprevir/ritonavir, Ombitasvir, Dasabuvir

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C | Status: COMPLETED | Results posted: 2019-03-14